Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.46 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949040 | 0.99 | ADORA3 (0.49) | ADORA3HTTNPSR1NR2E3CHEK2 | |
| SCHEMBL11949025 | 0.96 | CHEK2 (0.48) | HTTNR2E3CHEK2PRSS12SLC2A1 | |
| SCHEMBL11949008 | 0.90 | HTT (0.49) | HTTNPSR1NR2E3CHEK2KDR | |
| SCHEMBL11949043 | 0.89 | HTT (0.48) | HTTNPSR1NR2E3CHEK2KDM4E | |
| SCHEMBL11956754 | 0.89 | KDM4E (0.48) | HTTNPSR1NR2E3CHEK2PRSS12 | |
| SCHEMBL3092628 | 0.89 | KDM4E (0.52) | ADORA3HTTNPSR1NR2E3KDM4E | |
| SCHEMBL11949035 | 0.88 | KDM4E (0.48) | HTTNPSR1NR2E3CHEK2KDM4E | |
| SCHEMBL15275497 | 0.88 | NR2E3 (0.49) | HTTNPSR1NR2E3CHEK2KDR | |
| SCHEMBL15275494 | 0.87 | NR2E3 (0.48) | HTTNPSR1NR2E3CHEK2KDM4E | |
| SCHEMBL11949019 | 0.85 | SLC2A1 (0.52) | HTTCHEK2PRSS12SLC2A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| WO-2008130669-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | ADORA3 2198/4885HTT 3620/4885NPSR1 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.